Leen Kawas is an entrepreneur in the biotechnology industry. Currently, she serves as the Managing General Partner at Propel Bio Partners. Dr. Leen Kawas has a Ph.D. in molecular pharmacology, and leverages her business acumen and education to innovate breakthrough treatments, medications, and options to advance the medical field.
As the co-founder and Managing General Partner of Propel Bio Partners, Leen Kawas leads a venture capital firm dedicated to supporting groundbreaking life science technologies that improve human health outcomes while providing entrepreneurs with more than just financial backing—offering comprehensive expertise and operational guidance throughout their development journey.
Born and raised in Jordan, Leen Kawas immigrated to the United States in 2008, bringing with her a profound dedication to scientific advancement and healthcare improvement. Her academic journey began with a Bachelor of Science degree in Molecular and Cell Biology from the University of California, Berkeley, followed by a Ph.D. in Pharmacology and Toxicology from the University of Arizona. She also holds a Pharmacy degree from the University of Jordan and completed the Executive Training Program at the University of Washington, establishing a strong foundation in both scientific research and practical applications.
Leen Kawas's career trajectory reflects her exceptional talent for translating scientific innovation into commercial success. Prior to founding Propel Bio Partners, she co-founded a biotechnology company where she served as CEO from 2014 to 2021. During her tenure, she co-invented multiple novel drug candidates, including a lead candidate for the treatment of Alzheimer's disease. Her leadership skills were instrumental in guiding the company through multiple late-stage clinical programs and an initial public offering in 2020, which raised over $400 million.
As one of only 22 female founders and CEOs who led their companies to an IPO as of February 2021, Leen Kawas made history as the first woman in 20 years to take a company public in Washington State. This remarkable achievement underscores her ability to navigate the complex intersection of scientific innovation, regulatory requirements, and capital markets—a rare combination that distinguishes her within the biotechnology sector.
Throughout her career, Leen Kawas has been recognized for her exceptional leadership and contributions to the field. Her accolades include the Life Science Entrepreneurial Achievement Award (2020), recognition as a French-American Foundation Leader (2019), and GeekWire Startup CEO of the Year (2019).
Beyond her professional achievements, Leen Kawas maintains a strong commitment to mentorship and diversity within the biotechnology industry. She is a passionate supporter of scientist entrepreneurs, particularly women, and works to create more inclusive environments throughout the sector.
Leen Kawas's board service extends her influence and expertise throughout the biotechnology ecosystem. She serves on multiple industry-related boards, including Inherent Biosciences and Persephone Biosciences and is an active member of the Springboard Network. Her board participation also includes past service on the Life Science Washington Board, the Scientific Review Board for the Alzheimer's Drug Discovery Foundation, and the Alzheimer's Association's Washington Chapter Board.
